Mesoblast Limited
rexlemestrocel-L
chronic discogenic low back pain (CLBP)
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for rexlemestrocel-L in chronic discogenic low back pain (CLBP) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 15h ago
“Mesoblast has generated new data showing that a single administration of rexlemestrocel- L at the time of open heart surgery and device implantation to support the left ventricle in end-stage patients with HFrEF, reduces right heart failure”